Background: HIV infection, vascular perturbation, and central nervous system (CNS) dysfunction may associate through common pathogenic pathways of inflammation observed even in antiretroviral therapy (ART)-controlled HIV infection. We examined plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor and biomarker of endothelial dysfunction in participants recruited during primary HIV infection (PHI, < 365 days post infection, DPI), examining associations between ADMA and measures of systemic and CNS perturbation before and after ART and over time.
Methods: 25 ART-naïve PHI individuals were assessed at baseline and at an interval 6-12 months after initiating ART. Assessments included clinical blood measures, an 11 test neuropsychological battery (summarized as total Z and 4 test NPZ-4), and CSF total white blood cell count and albumin ratio. ADMA levels in PHI subjects were compared with published values in HIV-uninfected controls (HIV-, n=50) and chronically infected subjects (median 13 years duration infection) with viral suppression on ART (n=148) measured in the same laboratory. Nonparametric statistics were employed for analysis.
Results: PHI subjects were assessed at baseline at median 139 (IQR 54, 182) DPI and subsequently at median 281 (202, 372.5) days after ART initiated 256 (133, 744) DPI. At baseline, PHI participants had higher median ADMA 0.70 (0.62, 0.82) µM than historical HIV- (0.44 μM, 0.38, 0.46) and chronically HIV-infected subjects on ART (0.46 μM, 0.41, 0.52, p < 0.0001 for each comparison). ADMA levels in PHI did not change from baseline to post-ART (p=0.87), and remained elevated compared with HIV- and chronic, on-ART comparisons (p<0.0001 for each). In PHI, ADMA did not associate with total Z or NPZ4 pre- or post-ART, nor correlate over time with respect to change in each measure. Of laboratory measures, pre-ART ADMA associated with blood CD8+ T cell count (p=0.05), as previously reported in chronic infection.
Conclusions: At baseline, PHI subjects had ADMA levels higher than values from uninfected and chronically infected ART-treated historical comparisons, and ADMA elevation correlated with levels of blood CD8+ T cells, but not CNS measures. In contrast to prior findings in cross sectional studies of treated, suppressed chronic HIV subjects, ADMA levels in our subjects did not change after more than 9 months on ART initiated during early infection, suggesting ongoing endothelial dysfunction.